USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
SCARAB GENOMICS, LLC
Address:
1202 Ann St
MADISON, WI 53713-
EIN:
136449250
DUNS:
105975036
Number of Employees:
14
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $2,335,612.00 10
SBIR Phase II $7,577,446.00 5

Award List:

Engineered Revision of the E. coli Genome for Production

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): E. coli K-12 is well established as a preferred host for commercial production of recombinant DNA products including enzymes, vaccines, metabolites and DNA itself. The complete genome sequence of the E. coli bacterium has now been determined and it shows the… More

Engineering E. coli for periplasmic protein production

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$109,429.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Escherichia coli has numerous advantages as a host for the manufacture of recombinant proteins. So far, with a few notable exceptions, it has proven difficult to make disulfide bonded proteins in this host. The few successes have been achieved mainly by… More

Engineering E. coli for periplasmic protein production

Award Year / Program / Phase:
2004 / SBIR / Phase II
Award Amount:
$1,041,257.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Escherichia coli has numerous advantages as a host for the manufacture of recombinant proteins. So far, with a few notable exceptions, it has proven difficult to make disulfide bonded proteins in this host. The few successes have been achieved mainly by… More

Engineered Revision of E. coli for Production of DNA, Proteins and Metabolites

Award Year / Program / Phase:
2005 / SBIR / Phase II
Award Amount:
$1,337,275.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Our goal is to improve the versatility, safety and effectiveness of E. coli as a platform for commercial production of DNA, proteins and metabolites. The natural E. coli genome will be reduced to its essentials by removing unnecessary, detrimental and… More

Clean-Genome vaccines against biodefense agents

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$1,000,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Project description: We propose to develop a new vaccine delivery platform based on a non-pathogenic E. coli with specific safety features. Compared with other bacteria used for vaccines, the E. coli multi-deletion strain (MDS) has been extensively engineered,… More

Improved bacterial strains for therapeutic DNA production

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$139,203.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Principal Investigator/Program Director (Last, First, Middle): Blattner, Frederick R. Abstract: The goal of this proposal is to develop methods and strains for manufacturing plasmid DNA of extraordinary purity in very l arge quantity for therapeutic use.… More

Engineered revision of the E. coli Nissle 1917 Genome

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$141,037.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The ability of genetically modified probiotic (beneficial) bacteria to deliver therapeutic compounds is a promising new experimental method for delivering fragile and complex bio-molecules without injection. The long-t erm goal of this study is to improve the… More

Improved bacterial strains for therapeutic DNA and protein production

Award Year / Program / Phase:
2009 / SBIR / Phase II
Award Amount:
$1,825,983.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The goal of this Phase II proposal is to evaluate Scarab Genomics' improved E. coli production strains in real world conditions under which pharmacological grade therapeutic proteins and plasmid DNA are produced. In s ome cases this will be done in… More

Uniform length DNA for paired end nextgen sequencing via in vitro packaging

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$127,387.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): We have recognized an urgent need for a commercially applicable high throughput way to isolate pure DNA with long and uniform fragment length for nextgen genomic sequencing from precious samples. The advent of nextgen s equencing has driven the cost of DNA… More

Innate Immune Protection by Clean Genome E. coli

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$139,981.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Complications arising from pathogen infection incur a tremendous societal cost both in morbidity and mortality (as high as 50-60%), as well as in care and treatment estimated in billions of dollars. In susceptible patie nts, infection induces mis-regulation of… More

Innate Immune Protection by Clean Genome E. coli

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$1,748,517.00
Agency:
HHS
Principal Investigator:
Frederick R. Blattner – 608-257-1624
Abstract:
DESCRIPTION (provided by applicant): Complications arising from pathogen infection incur a tremendous societal cost both in morbidity and mortality (as high as 50-60%), as well as in care and treatment estimated in billions of dollars. In susceptible patients, infection induces mis-regulation of the… More

Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$140,925.00
Agency:
HHS
Principal Investigator:
Frederick R. Blattner – 608-257-1624
Abstract:
DESCRIPTION (provided by applicant): Scarab Genomics has developed valuable reduced-genome strains of Escherichia coli in which multiple deletions remove from the genome much unwanted and all potentially hazardous DNA. These Clean Genome(R) strains, alongwith Scarab's gene expression… More

A protease-deficient, low mutation rate E. coli for biotherapeutics production

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$155,032.00
Agency:
HHS
Principal Investigator:
Frederick R. Blattner – 608-257-1624
Abstract:
DESCRIPTION (provided by applicant): Biotherapeutics is a fast-growth sector in the pharmaceutical market with monoclonal antibodies accounting for almost 50% of the 100 billion USD spent each year on protein therapies. Bacterial fermentation, which accounts for about 35% of all protein therapeutics… More

Characterization of a low mutation rate E. coli in extended fermentation

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$282,618.00
Agency:
HHS
Principal Investigator:
Frederick R. Blattner – 608-257-1624
Abstract:
DESCRIPTION (provided by applicant): This application aims to test a new Scarab E. coli strain, MDS42pdu, for commercial fermentation to produce biopharmaceuticals, amino acids and biofuels. It is designed for a very low rate of point mutations and Insertion Sequence transposition, especially in the… More

A protease-deficient, low mutation rate E. coli for biotherapeutics production

Award Year / Program / Phase:
2013 / SBIR / Phase II
Award Amount:
$1,624,414.00
Agency:
HHS
Principal Investigator:
Frederick R. Blattner – 608-257-1624
Abstract:
DESCRIPTION (provided by applicant): Biotherapeutics is a fast-growth sector in the pharmaceutical market with monoclonal antibodies accounting for almost 50% of the 100 billion USD spent each year on protein therapies. Bacterial fermentation, which accounts for about 35% of all protein therapeutics… More